Identification of Liver Fibrosis Biomarkers

Inclusion Criteria: * Patients scheduled for biopsy (or F0-F2 patients that underwent biopsy within the last 6 months but at least 1 month ago) suspected of having hepatic fibrosis due to NAFLD (NAFL/NASH) or patients with MASLD or MASH * Any FIB-4 value available * Any Fibroscan value available * Written and signed informed consent present * Patients aged ≥ 18 years to ≤ 75 years at the time of the blood draw * Body Mass Index (BMI) ≤ 45 kg/m² Exclusion Criteria: * Vulnerable person: person deprived of liberty by a judicial or administrative decision and/or person under psychiatric care * Self-reported pregnancy or lactating females * Disease related to other etiologies, including alcoholic liver disease (alcoholic steatohepatitis), MetALD, specific etiology SLD (e.g. DILI or monogenic disease), cryptogenic SLD, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, Wilson's disease, Hemochromatosis, alpha-1 antitrypsin deficiency * Any type of carcinoma, unless it is at least 5 years in remission * Prior liver transplant * Evidence of any other unstable or, untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric disorder. Medically controlled comorbidities can be allowed * Self-reported alcohol consumption greater 30 g/day (males) 20 g/day (females) * Recent myocardial infarction (within last 6 months) * Inability to have a liver biopsy, or provide blood sample in a fasted status * F0-F2 recalled patients with +/- 5% change in weight between the biopsy and study inclusion